Zhongsheng H. Tong
Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100730, China
Beijing, 100730, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications
Retraction notice to "Circ_0084653 promotes the tumor progression and immune escape in triple-negative breast cancer via the deubiquitination of MYC and upregulation of SOX5" [International Journal of Biological Macromolecules 280 (2024) 135655].
Journal: International journal of biological macromolecules
Published: July 21, 2026
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 01, 2026
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.
Journal: Biomolecules & biomedicine
Published: April 23, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: March 19, 2026
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Journal: BMJ (Clinical research ed.)
Published: March 16, 2026
Annual progress in pulmonary rehabilitation in 2025
Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: February 02, 2026
Efficacy and reproducibility of a novel robotic-assisted system for anterior cruciate ligament reconstruction in in vitro bone tunnel drilling
Journal: Zhonghua yi xue za zhi
Published: January 03, 2026
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
Journal: Cancer communications (London, England)
Published: December 09, 2025
Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study.
Journal: Frontiers in pharmacology
Published: November 30, 2025
Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study.
Journal: Breast (Edinburgh, Scotland)
Published: November 28, 2025
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 14, 2025
Cognitive impairment in long COVID: advances in pathological mechanisms and exercise rehabilitation interventions
Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: November 11, 2025
Last Updated: 09/26/2026